7 extractive question-and-answer pairs built from ICMR Standard Treatment Workflow (STW) BREAST CANCER, published by icmr.gov.in. The source is a 1-page publication. Source-evidenced topics include standard treatment workflow, breast cancer, icd-10-c 50, triple assessment, clinical breast examination, imaging, bilateral mammogram, ultrasound. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. Question types in the export: 3 definition, 2 list, 1 factual, 1 relationship. 6 of the 7 pairs (85.7%) ask explanatory questions; the remaining 1 are factual or table-based questions. 100.00% of rows pass the corpus quality gate.
This dataset contains seven extractive question-and-answer pairs derived from the ICMR Standard Treatment Workflow for breast cancer. The questions cover definitions, lists, relationships, and factual details about breast cancer management, imaging techniques, and systemic changes. Each answer is a direct excerpt from the source document, ensuring accuracy and traceability. The dataset focuses on clinical terms and procedures such as PET-CT scans, axillary lymph node dissection, and triple assessment methods.
Browse more health datasets, including other records from the same source when available.
Explore Health datasets1725952331_psychiatry_all - Question and Answer Dataset
Economy · 176 rows
ICMR Standard Treatment Workflow (STW) SUPRACONDYLAR FRACTURE OF HUMERUS IN CHILDREN - Question and Answer Dataset
Economy · 22 rows
1726569102_ophthalmology_all - Question and Answer Dataset
Health · 77 rows
1725952349_ent - Question and Answer Dataset
Health · 178 rows
NFHS-5 Dataset
Health · 3.8K+ rows
National Health Profile 2022 - Question and Answer Dataset
Health · 5.7K+ rows
National Health Profile 2022 — Question and Answer Dataset
Health · 5.7K+ rows
XVFC VOL I Main Report - Question and Answer Dataset
Health · 1.7K+ rows
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/www-icmr-gov-in-172c4b03627558d1f111616a250fdd38/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("www-icmr-gov-in-172c4b03627558d1f111616a250fdd38")
df.head()First 7 of 7 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_document | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| What does the abbreviation PET-CT refer to in imaging? | Positron emission tomography- computed tomography scan | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 305 | definition | 1.000 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 1 | page=1,block=69 | 0.700 | valid |
| What does the abbreviation ALND stand for in breast cancer management? | Axillary lymph node dissection | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 31 | definition | 0.940 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 1 | page=1,block=69 | 0.700 | valid |
| What does the abbreviation FISH stand for in breast cancer pathology? | Fluorescence in situ hybridization | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 159 | definition | 0.940 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Primary systemic therapy ALND: Axillary lymph node dissection CECT: Contrast-enhanced computed tomography ER/PR: Estrogen receptor/Progesterone receptor FISH: Fluorescence in situ hybridization HER2: Human epidermal growth factor receptor 2 IHC: Immunohistochemistry MBC: Metastatic breast cancer PET-CT: Positron emission tomography- computed tomography scan RT: Radiotherapy SLNB: Sentinel lymph node biopsy | 1 | page=1,block=69 | 0.700 | valid |
| What type of spread can cause symptoms like headache, jaundice, and bone pains in breast cancer? | Distant spread | A. Asymmetry of breast or nipple areola or axilla B. Breast lump, bulge, blood vessels prominent C. Colour change of skin or nipple areola D. Deformed breast / nipple areola (nipple retraction), dimpling of skin, Discharge from nipple, Direct spread-skin (satellite nodule, ulcer, skin oedema), chest wall Distant spread - headache, jaundice, dyspnoea, bone pains, ascites CLINICAL BREAST EXAMINATION IMAGING • Bilateral mammogram: for women >30 years • Ultrasound: breast and axilla • MRI breast in selected cases STAGING- T1, T2 N0 N1 Upto Stage 2A no metastatic work up Stage 2B upwards • Chest radiograph • Ultrasound whole abdomen • Bone scan • CECT chest and abdomen • PET-CT (optional) PATHOLOGY • Core needle biopsy (preferred) for type, grade, ER, PR, HER2/neu, Ki-67 • FISH test if HER-2/neu on IHC-2+/ equivocal | 306 | relationship | 0.890 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Deformed breast / nipple areola (nipple retraction), dimpling of skin, Discharge from nipple, Direct spread-skin (satellite nodule, ulcer, skin oedema), chest wall Distant spread - headache, jaundice, dyspnoea, bone pains, ascites CLINICAL BREAST EXAMINATION IMAGING • Bilateral mammogram: for women >30 years • Ultrasound: breast and axilla • MRI breast in selected cases STAGING- T1, T2 N0 N1 Upto Stage 2A no metastatic work up Stage 2B upwards • Chest radiograph • Ultrasound whole abdomen • Bone scan • CECT chest and abdomen • PET-CT (optional) PATHOLOGY • Core needle biopsy (preferred) for | ||||
| What are the components of the triple assessment for breast cancer? | CBE, USG breast and axilla, mammography and core biopsy | Triple assessment (CBE, USG breast and axilla, mammography and core biopsy For axilla (clinico-radiological assessment) For breast Node -ve -ve +ve SLNB/axillary sampling ALND No ALND Neoadjuvant systemic therapy Discuss extent of surgery MRM or Breast conservation surgery Adjuvant systemic treatment therapy +RT surgery No metastasis Yes metastasis Locally Advanced Breast Cancer Intent of treatment: curative Metastatic Breast Cancer Intent of treatment: palliative care Consider hormone therapy chemotherapy targeted therapy as clinically indicated ENHANCE AWARENESS AND EARLY DETECTION OF BREAST CANCER BY SCREENING AS PER NATIONAL PROGRAMME | 19 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Triple assessment (CBE, USG breast and axilla, mammography and core biopsy For axilla (clinico-radiological assessment) For breast Node -ve -ve +ve SLNB/axillary sampling ALND No ALND Neoadjuvant systemic therapy Discuss extent of surgery MRM or Breast conservation surgery Adjuvant systemic treatment therapy +RT surgery No metastasis Yes metastasis Locally Advanced Breast Cancer Intent of treatment: curative Metastatic Breast Cancer Intent of treatment: palliative care Consider hormone therapy chemotherapy targeted therapy as clinically indicated ENHANCE AWARENESS AND EARLY DETECTION OF | ||||
| What surgical options are discussed after neoadjuvant systemic therapy for breast cancer? | MRM or Breast conservation surgery | Triple assessment (CBE, USG breast and axilla, mammography and core biopsy For axilla (clinico-radiological assessment) For breast Node -ve -ve +ve SLNB/axillary sampling ALND No ALND Neoadjuvant systemic therapy Discuss extent of surgery MRM or Breast conservation surgery Adjuvant systemic treatment therapy +RT surgery No metastasis Yes metastasis Locally Advanced Breast Cancer Intent of treatment: curative Metastatic Breast Cancer Intent of treatment: palliative care Consider hormone therapy chemotherapy targeted therapy as clinically indicated ENHANCE AWARENESS AND EARLY DETECTION OF BREAST CANCER BY SCREENING AS PER NATIONAL PROGRAMME | 239 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf | Triple assessment (CBE, USG breast and axilla, mammography and core biopsy For axilla (clinico-radiological assessment) For breast Node -ve -ve +ve SLNB/axillary sampling ALND No ALND Neoadjuvant systemic therapy Discuss extent of surgery MRM or Breast conservation surgery Adjuvant systemic treatment therapy +RT surgery No metastasis Yes metastasis Locally Advanced Breast Cancer Intent of treatment: curative Metastatic Breast Cancer Intent of treatment: palliative care Consider hormone therapy chemotherapy targeted therapy as clinically indicated ENHANCE AWARENESS AND EARLY DETECTION OF | ||||
| What systemic change can indicate breast cancer involving the liver? | Enlarged liver | Evaluation and management by multidisciplinary team (MDT) of oncology experts SIGNS A Breast changes • Asymmetry in shape/size of breast or nipple areola complex • Breast lump • Nipple retraction/ulcer • Change in skin - puckering, dimpling, thickening, ulcer, redness, edema & satellite nodules • Fixity to underlying muscles or chest wall B Lymph node • lymph node(s) in axilla or supra-clavicular fossa C Systemic changes • Enlarged liver, ascites, bony tenderness, dyspnoea, pleural effusion ADJUVANT THERAPY (AT) Chemotherapy • Consider for all patients with pT > 1 cm or node positive disease based on ER/PR/HER2 /Ki-67 Radiotherapy • After breast conservation surgery • After mastectomy with node-positive disease or pathological T3/T4 Targeted therapy • All HER-2/neu positive (3+) or FISH HER-2 amplified patients should receive trastuzumab for 12 months • Shorter schedules: 9 weeks to 6 months acceptable in some patients Hormone therapy • All ER and /or PR positive cases • For premenopausal women tamoxifen and for post menopausal women tamoxifen or aromatase inhibitors are appropriate • Minimum for 5 years, if high risk of recurrence like node positive, consider for up to 10 years • If AT is used zolendronic acid or other bisphosphonates can be added | 427 | factual | 0.490 |
Read straight from the file — download or use the API URL for the full dataset.
| 1 |
| page=1,block=7 |
| 0.700 |
| valid |
| 1 |
| page=1,block=25 |
| 0.700 |
| valid |
| 1 |
| page=1,block=25 |
| 0.700 |
| valid |
| https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568905_breast_cancer.pdf |
| Evaluation and management by multidisciplinary team (MDT) of oncology experts SIGNS A Breast changes • Asymmetry in shape/size of breast or nipple areola complex • Breast lump • Nipple retraction/ulcer • Change in skin - puckering, dimpling, thickening, ulcer, redness, edema & satellite nodules • Fixity to underlying muscles or chest wall B Lymph node • lymph node(s) in axilla or supra-clavicular fossa C Systemic changes • Enlarged liver, ascites, bony tenderness, dyspnoea, pleural effusion ADJUVANT THERAPY (AT) Chemotherapy • Consider for all patients with pT > 1 cm or node positive disease |
| 1 |
| page=1,block=14 |
| 0.700 |
| valid |